Intramuscular administration of DNA vaccines can lead to the generation of antigen-specific immune responses through cross-priming mechanisms. We propose a strategy that is capable of leading to local inflammation and enhancing crosspriming, thus resulting in improved antigen-specific immune responses. Therefore, in this study, we evaluated the immunological responses elicited through electroporationmediated intramuscular administration of a DNA vaccine encoding calreticulin (CRT) linked to human papillomavirus type 16 E7 (CRT-E7) in combination with DNA expressing HLA-A2 as compared with CRT-E7 DNA vaccination alone. We found that the co-administration of a DNA vaccine in conjunction with a DNA encoding a xenogenic major histocompatibility complex (MHC) molecule could significantly enhance the E7-specific CD8+ T-cell immune responses and antitumor effects against an E7-expressing tumor, TC-1, in C57BL/6 tumor-bearing mice. Furthermore, a similar enhancement in E7-specific immune responses was observed by the co-administration of CRT-E7 DNA with DNA encoding other types of xenogenic MHC class-I molecules. This strategy was also applicable to another antigenic system, ovalbumin. Further characterization of the injection site revealed that the co-administration of HLA-A2 DNA led to a significant increase in the number of infiltrating CD8+ T lymphocytes and CD11b/ c+ antigen-presenting cells. Furthermore, the E7-specific immune responses generated by intramuscular co-administration of CRT-E7 with HLA-A2 DNA were reduced in HLA-A2 transgenic mice. Thus, our data suggest that intramuscular co-administration of DNA encoding xenogenic MHC class-I can further improve the antigen-specific immune responses, as well as antitumor effects generated by DNA vaccines through enhancement of cross-priming mechanisms.
Introduction
Deoxyribose nucleic acid vaccines have emerged as a potentially promising approach for cancer immunotherapy based on their safety, stability and ease of preparation (for review, see Donnelly et al. 1 and Gurunathan et al. 2 ). However, naked DNA vaccines suffer from limited immunogenicity and therefore, require additional strategies to improve their ability to generate strong immune responses. We have developed a number of innovative strategies to enhance DNA vaccine potency (for review, see Hung et al. 3 and Tsen et al. 4 ). One approach to enhance DNA vaccine potency is the employment of a molecule that is capable of binding with molecules expressed on dendritic cells. For example, we have previously developed a DNA vaccine encoding the human papillomavirus type 16 E7 antigen linked to a chaperone protein, calreticulin (CRT) (CRT-E7 DNA). 5, 6 We have employed the CRT-E7 DNA vaccine in several recent studies using the intradermal administration via gene gun. [7] [8] [9] We have also shown that intramuscular administration of DNA vaccines encoding CRT-E7 induced strong E7-specific CD8+ T-cell immune responses. 10 Intramuscular administration of DNA vaccines is a commonly used method for the administration of DNA vaccines (for review see Bodles-Brakhop et al. 11 and Hung et al. 13 ). However, this approach can result in suboptimal immunogenicity despite the introduction of high concentrations of injected plasmid. 14 Intramuscular administration of DNA vaccines may be enhanced by the employment of electroporation (for reviews see Luxembourg et al. 15 and Roles 16 ). Electroporation involves the administration of a naked DNA plasmid into muscle by needle injection, followed by a brief electrical pulse to the surrounding tissue. A transient increase in the permeability of the plasma membrane induced by the electrical current allows increased uptake and, thus, expression of the DNA plasmid. 17, 18 In addition to the increased uptake of DNA by myocytes resulting in increased protein expression levels of the target antigen, pro-inflammatory cytokines and monocytes/macrophages are also recruited to the site of vaccination, which can enhance antigen presentation to the immune system. 19 In fact, electroporation has been shown to significantly enhance the potency of therapeutic human papillomavirus DNA vaccines compared with other forms of administration. 20 Intramuscular administration of DNA vaccines by electroporation has been shown to lead to the generation of antigen-specific immune responses through crosspriming mechanisms. 21 In general, myocytes do not serve as efficient antigen-presenting cells, as they lack costimulatory molecules. Furthermore, as myocytes are not normally surrounded by lymphocytes, this restricts their ability to prime naïve T cells. Thus, DNA vaccines administered intramuscularly will most likely require the release of antigen expressed by myocytes, which can then be uptaken by professional antigen-presenting cells to prime antigen-specific T cells (so-called cross-priming). Thus, we reasoned that a strategy that is capable of leading to local inflammation and release of antigen from the myocytes may potentially enhance the cross-priming of antigen-specific T cells, resulting in improved antigenspecific T-cell immune responses generated by DNA vaccination.
Therefore, in this study, we evaluated immunological responses elicited through the administration of CRT-E7 DNA vaccine in combination with DNA encoding a xenogenic major histocompatibility complex (MHC) molecule followed by electroporation. We found that the co-administration of a DNA vaccine in conjunction with HLA-A2 DNA could significantly enhance the E7specific CD8+ T-cell immune responses, as well an antitumor effects against an E7-expressing tumor, TC-1, in C57BL/6 tumor-bearing mice. Furthermore, a similar enhancement in E7-specific immune responses was observed by the co-administration of CRT-E7 DNA with DNA encoding other types of xenogenic MHC class-I molecules. This strategy was also applicable to other antigenic systems, such as ovalbumin. Furthermore, the E7-specific immune responses generated by intramuscular co-administration of CRT-E7 with HLA-A2 DNA were reduced in HLA-A2 transgenic mice. Further characterization of the injection site revealed that the co-administration of HLA-A2 DNA led to a significant increase in the number of infiltrating CD8+ T lymphocytes and CD11b/c+ antigen-presenting cells. This strategy may potentially be used in other antigenic systems for the control of infectious diseases and/or cancer.
Results
Intramuscular vaccination with CRT-E7 DNA in conjunction with HLA-A2 DNA followed by electroporation generates significantly higher frequency of E7-specific CD8+ T cells in vaccinated mice
In order to determine the E7-specific CD8+ T-cell immune response in mice vaccinated with CRT-E7 DNA with HLA-A2 DNA, we vaccinated C57BL/6 mice (5 per group) intramuscularly with CRT/E7 DNA mixed with no insert or HLA-A2 DNA followed by electroporation twice with a 1-week interval. One week after the last vaccination, splenocytes from vaccinated mice were harvested and characterized for the presence of E7-specific CD8 + T cells in treated mice using intracellular cytokine staining for IFN-g followed by flow cytometry analysis. As shown in Figure 1 , mice vaccinated with CRT-E7 DNA with HLA-A2 DNA generated a significantly higher number of E7-specific CD8 + T cells compared with mice vaccinated with CRT-E7 DNA with backbone DNA (no insert). These results indicate that co-administration of HLA-A2 DNA can significantly CRT/E7 
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Figure 1 Intracellular cytokine staining followed by flow cytometry analysis to characterize the E7-specific CD8+ T cell immune response in vaccinated mice. C57BL/6 mice (five per group) were immunized with CRT-E7 DNA mixed with no insert or HLA-A2 DNA intramuscularly followed by electroporation twice with a 1-week interval. One week after the last vaccination, splenocytes from vaccinated mice were harvested and stimulated with the E7 peptide. Cells were characterized for E7-specific CD8 + T cells using intracellular IFN-g staining followed by flow cytometry analysis. Splenocytes without peptide stimulation were used as negative control. Xenogenic MHC class-I DNA with CRT-E7 DNA vaccination TH Kang et al enhance the E7-specific CD8+ T cell immune responses generated by CRT-E7 DNA vaccination. We also characterized the HLA-A2-specific CD8+ Tcell immune responses in vaccinated mice. We observed that mice vaccinated with CRT-E7 DNA with HLA-A2 DNA generated a significantly higher number of HLA-A2-specific CD8 + T cells compared with mice vaccinated with CRT-E7 DNA with backbone DNA (no insert) (See Supplementary Figure 2 ).
TC-1 tumor-bearing mice treated with CRT-E7 DNA vaccine in conjunction with HLA-A2 DNA generate significantly better therapeutic antitumor effects
To determine the therapeutic antitumor effects generated by HLA-A2 DNA in conjunction with CRT-E7 DNA vaccination, we first challenged groups of C57BL/6 mice (five per group) through tail vein with TC-1 tumor cells and then treated them with CRT-E7 DNA with or without HLA-A2 DNA intramuscularly followed by electroporation. Tumor-bearing mice treated with pcDNA3-no insert were used as negative controls. As shown in Figure 2a , tumor-bearing mice treated with HLA-A2 DNA with CRT-E7 DNA showed significantly reduced number of pulmonary tumor nodules as compared with tumor-bearing mice treated with DNA vaccine alone (Po0.002).
We also tested the long-term antitumor effects of vaccinated mice using a tumor prevention experiment. C57BL/6 mice (five per group) were vaccinated with CRT-E7 DNA with or without HLA-A2 DNA intramuscularly followed by electroporation twice with a 1-week interval. Seven weeks after the last vaccination, mice were subcutaneously challenged with 1 Â l0 5 of TC-1 cells per mouse in the right leg and the long-term survival was evaluated. As shown in Figure 2b , mice vaccinated with HLA-A2 DNA with CRT-E7 DNA showed improved long-term survival compared with mice vaccinated with HLA-A2 DNA alone or the DNA vaccine alone (Po0.0001). Thus, our data indicate that the treatment with HLA-A2 DNA can significantly enhance the therapeutic and preventive antitumor effects generated by CRT-E7 DNA vaccination in TC-1 tumorbearing mice.
Vaccination with CRT-E7 DNA in conjunction with DNA encoding different xenogenic MHC class-I is capable of generating a significantly higher frequency of E7-specific CD8+ T cells in vaccinated mice
In order to determine if the observed enhancement in E7-specific CD8+ T-cell immune response in vaccinated mice by HLA-A2 DNA is applicable to other xenogenic MHC class-I molecules, we vaccinated C57BL/6 mice (five per group) with CRT-E7 DNA mixed with DNA encoding other xenogenic MHC class-I molecules including HLA-A3, HLA-A24 and HLA-A2 intramuscularly followed by electroporation twice with a 1-week interval. One week after the last vaccination, splenocytes from vaccinated mice were harvested and characterized the presence of E7-specific CD8 + T cells in treated mice using intracellular cytokine staining for IFN-g followed by flow cytometry analysis. As shown in Figure 3 , mice vaccinated with CRT-E7 DNA in conjunction with DNA encoding any of the xenogenic MHC class-I molecules generated a significantly higher number of E7-specific CD8 + T cells compared with mice vaccinated with CRT-E7 DNA with backbone DNA (no insert). Among the various xenogenic MHC class-I molecules tested, HLA-A2 DNA generated the highest E7-specific immune In vivo tumor treatment and prevention experiments. (a) Bar graph depicting the number of pulmonary tumor nodules in TC-1 tumor bearing mice treated with CRT-E7 and/or HLA-A2 DNA. C57BL/6 mice (five per group) were challenged through tail vein with 2 Â 10 5 of TC-1 tumor cells per mouse. Four days later, the mice were immunized with 2 mg of pcDNA-No insert, 1 mg of HLA-A2 mixed 1 mg of pcDNA3-no insert, 1 mg of CRT-E7 mixed 1 mg of pcDNA3-No insert or 1 mg of CRT-E7 mixed 1 mg of HLA-A2 intramuscularly followed by electroporation twice with a 1-week interval. Tumor growth was monitored over time and survival of tumor-bearing mice was analyzed by Kaplan and Meier analysis. The data are expressed as mean number of pulmonary lung nodules ± s.d. twice with a 1-week interval. (b) Kaplan and Meier survival analysis of TC-1 tumor challenged mice treated with mice treated with CRT-E7 and/or HLA-A2 DNA. C57BL/6 mice (five per group) were vaccinated with 2 mg of pcDNA-No insert, 1 mg of HLA-A2 mixed 1 mg of pcDNA3-No insert, 1 mg of CRT-E7 mixed with 1 mg of pcDNA3-No insert or 1 mg of CRT-E7 mixed with 1 mg of HLA-A2 intramuscularly followed by electroporation twice with a 1-week interval. Seven weeks after the last vaccination, mice were subcutaneously challenged with 1 Â l0 5 TC-1 cells per mouse in the right leg and long-term survival was evaluated. Mice were monitored for evidence of survival by palpation and inspection twice a week. Data shown are representative of two experiments performed.
Xenogenic MHC class-I DNA with CRT-E7 DNA vaccination TH Kang et al responses. These results indicate that the observed enhancement in E7-specific CD8+ T-cell immune response in mice vaccinated with CRT-E7 DNA in conjunction with HLA-A2 DNA is also applicable to other xenogenic MHC class-I molecules.
Vaccination with OVA-specific DNA vaccine in conjunction with HLA-A2 DNA generates a significantly higher frequency of OVA-specific CD8+ T cells in vaccinated mice
In order to determine if the observed enhancement in E7-specific CD8+ T-cell immune response in vaccinated mice can be applied to other antigenic systems, we vaccinated C57BL/6 mice (5 per group) with DNA encoding ovalbumin (OVA) mixed with no insert or HLA-A2 DNA intramuscularly followed by electroporation twice with a 1-week interval. One week after the last vaccination, splenocytes from vaccinated mice were harvested and characterized for the presence of OVAspecific CD8 + T cells in treated mice using intracellular cytokine staining for IFN-g followed by flow cytometry analysis. As shown in Figure 4 , mice vaccinated with OVA DNA mixed with HLA-A2 DNA generated a significantly higher number of OVA-specific CD8 + T cells compared with mice vaccinated with OVA DNA with backbone DNA (no insert). These results indicate that the ability of DNA encoding xenogenic MHC molecules to enhance the antigen-specific CD8+ T-cell immune responses generated by DNA vaccination can be applied to other antigenic systems, such as ovalbumin.
Vaccination with CRT-E7 DNA in conjunction with HLA-A2 DNA fails to generate significantly higher frequency of E7-specific CD8+ T cells in vaccinated HLA-A2 transgenic mice
In order to determine whether the observed enhancement in E7-specific CD8+ T-cell immune response by co-administration of DNA encoding HLA-A2 will occur in HLA-A2 transgenic mice, we vaccinated HLA-A2 transgenic mice (five per group) with CRT-E7 DNA mixed with no insert or HLA-A2 DNA intramuscularly followed by electroporation twice with a 1-week interval. One week after the last vaccination, splenocytes from vaccinated mice were harvested and characterized for the presence of E7-specific CD8 + T cells in treated mice using intracellular cytokine staining for IFN-g followed by flow cytometry analysis. As shown in Figure 5 , HLA-A2 transgenic mice vaccinated with CRT-E7 DNA mixed with HLA-A2 DNA generated comparable number of E7-specific CD8 + T cells compared with mice vaccinated with CRT-E7 DNA with backbone DNA (no insert). These results indicate that coadministration of DNA encoding xenogenic MHC molecules is required to enhance the antigen-specific CD8+ T-cell immune responses generated by DNA vaccination. No insert HLA A3 HLA A24 HLA A2 Figure 3 Intracellular cytokine staining and flow cytometry analysis to characterize the antigen-specific CD8 + T-cell response by vaccination with various xenogenic major histocompatibility complex (MHC) class-I DNA. C57BL/6 mice (five per group) were immunized with CRT-E7 DNA mixed with no insert or HLA-A2, HLA-A3 and HLA-A24 DNA intramuscularly followed by electroporation twice with a 1-week interval. One week after the last vaccination, splenocytes from vaccinated mice were harvested and stimulated with the E7 peptide. Cells were characterized for E7-specific CD8 + T cells using intracellular IFN-g staining followed by flow cytometry analysis. Splenocytes without peptide stimulation were used as negative control. In order to investigate the mechanisms of the observed enhancement in E7-specific CD8+ T-cell immune response by co-administration of DNA encoding HLA-A2, C57BL/6 mice were injected with pcDNA-no insert or HLA-A2 DNA by intramuscular injection followed by electroporation. Muscle sections from the site of injection was removed on days 3 and 5 and characterized for the presence of CD8 and CD11b/c immune cells. As shown in Figure 6a , muscle sections from mice injected with HLA-A2 demonstrated a significant increase in the number of F4/80+ inflammatory cells, the number of infiltrating CD8+ T lymphocytes and CD11b/c+ antigenpresenting cells compared with sections from mice injected with pcDNA-no insert. In addition, we found that the number of F4/80+ inflammatory cells and CD11b/c+ cells decreased over a period of time. The number of CD8+ T lymphocytes were slightly increased on day 5 compared with day 3, but significantly decreased on day 7 (Figure 6b ). We further characterized the luciferase expression in C57BL/6 mice injected intramuscularly with DNA-encoding luciferase in conjunction with HLA-A2 DNA or luciferase DNA alone Figure 4 Intracellular cytokine staining followed by flow cytometry analysis to characterize the ovalbumin (OVA)-specific CD8+ T-cell immune response in vaccinated mice. C57BL/6 mice (five per group) were immunized with pcDNA3 OVA mixed with pcDNA3 HLA-A2 or no insert intramuscularly followed by electroporation twice with a 1-week interval. One week after the last vaccination, splenocytes from vaccinated mice were harvested and stimulated with the OVA peptide. Cells were characterized for OVA-specific CD8 + T cells using intracellular IFN-g staining followed by flow cytometry analysis. Splenocytes without peptide stimulation were used as negative control. Figure 5 Intracellular cytokine staining followed by flow cytometry analysis to characterize the E7-specific CD8+ T cell immune response in vaccinated HLA-A2 transgenic mice. HLA-A2 transgenic mice (five per group) were immunized with CRT-E7 DNA mixed with no insert or HLA-A2 DNA intramuscularly followed by electroporation twice with a 1-week interval. One week after the last vaccination, splenocytes from vaccinated mice were harvested and stimulated with the E7 peptide. Cells were characterized for E7-specific CD8 + T cells using intracellular IFN-g staining followed by flow cytometry analysis. Splenocytes without peptide stimulation were used as negative control. 
Discussion
In this study, we observed that the co-administration of a DNA vaccine in conjunction with DNA encoding xenogenic MHC class-I molecules could significantly enhance the E7-specific CD8+ T-cell immune responses and antitumor effects against TC-1 in C57BL/6 tumorbearing mice. This strategy was also applicable to other antigenic systems, such as ovalbumin. Furthermore, the ability to enhance the antigen-specific immune responses is clearly because of the co-administration of xenogenic MHC class-I DNA, as co-administration of CRT-E7 with HLA-A2 DNA failed to enhance the immune responses in HLA-A2 transgenic mice. Further characterization of the injection site revealed that co-administration of HLA-A2 DNA led to a significant increase in the number of infiltrating CD8+ T lymphocytes and CD11b/c+ immune cells, as well as a reduction of protein expressing cells in the injection site. Thus, our data suggest that the intramuscular co-administration of DNA encoding xenogenic MHC class-I can further improve the antigen-specific immune responses, as well as antitumor effects generated by DNA vaccines, possibly through the enhancement of cross-priming mechanisms.
The encouraging results from this study suggest the possibility that other pro-inflammatory molecules and cytokines may potentially be used to enhance the immune responses generated by DNA vaccination administered intramuscularly. It has previously been shown that the coadministration of DNA vaccines with DNA encoding proinflammatory cytokines such as GM-CSF 22 and IL-12 23 intramuscularly results in the enhancement of antigenspecific immune responses and antitumor effects in vaccinated animals (for reviews see Tsen et al. 4 and Lori et al. 24 ). It is quite likely that these molecules may lead to a local inflammatory response, thus resulting in the increased release of antigen from muscle cells.
Our data demonstrate that the co-administration of HLA-A2 DNA leads to an increase in the number of F4/ 80+ inflammatory cells, infiltrating CD8+ T lymphocytes and CD11b/c+ antigen-presenting cells to the injection site ( Figure 6 ). The presence of antigen-presenting cells in the injection site raises the possibility that cross-priming may occur in the local environment in the vicinity of antigen-expressing cells in addition to the draining lymph nodes. It has been shown that dendritic cells can be recruited to the local tissues for CD8+ T-cell crosspriming. 25 Thus, it is conceivable that the inflammation generated by co-administration of xenogenic MHC class-I DNA may lead to the recruitment of antigen-presenting cells, resulting in cross-priming in the local muscle tissue in addition to the draining lymph nodes.
For clinical translation it is important to consider issues related to the safety of the vaccination. As this approach leads to local inflammation in the injection site, it may raise concerns for myositis. Although our data demonstrate that the mice injected with HLA-A2 DNA demonstrated significant local inflammation in the muscle on day 3 following injection, inflammation gradually reduced five days after the injection ( Figure  6 ) and eventually the mice completely recover from the injection. Thus, we expect that DNA vaccination with this approach may not create issues related to myositis based on our preclinical data.
In summary, our results demonstrate that intramuscular co-administration of DNA-encoding xenogenic MHC class-I followed by electroporation can improve the antigen-specific immune responses and antitumor effects generated by DNA vaccines through the enhancement of cross-priming mechanisms. Our study represents a new approach that may potentially be used in other antigenic systems for the control of infectious diseases and/or cancer.
Materials and methods
Mice Six-to eight-week-old female C57BL/6 mice were purchased from the National Cancer Institute (Frederick, MD, USA). HLA-A2 transgenic mice (C57BL/6-Tg(HLA-A2.1)1Enge/J) were purchased from The Jackson Laboratory (Bar Harbor, ME, USA). All animal procedures were carried out according to approved protocols and in accordance with recommendations for the proper use and care of laboratory animals.
Generation and characterization of plasmid DNA constructs
The generation of pcDNA3-CRT-E7, 5 pcDNA3-OVA 26 and pcDNA3-Luc 26 has been described previously. pcDNA3-HLA A2, HLA A3 and HLA A24 were kindly provided by Dr Elizabeth M Jaffee at Johns Hopkins University. For the generation of pcDNA3-HLA-A2/Luc, HLA-A2 DNA fragments was amplified by PCR using primers 5 0 -AAATCTAGAATGGCCGTCATGGCGCCCCG 3 0 and 5 0 -AAAGAATTCCACTTTACAAGCTGTGAG-3 0 and previously described pcDNA3-HLA-A2 vector as the template. The amplified DNA products were cloned into the XbaI/EcoRI sites of pcDNA3 vector (no stop). And then the luciferase DNA fragment was isolated from pcDNA3-Luc by PCR using primers 5 0 -AAAGAATTCATGGAA GACGCCAAAAAC-3 0 and 5 0 -AAAGGATCCTTACACGG CGATCTTTCC-3 0 and cloned into EcoRI/BamHI sites of pcDNA3-HLA-A2(no stop). The target gene HLA-A2 in recombinant pcDNA3-HLA-A2/Luc was then confirmed by sequencing and the expression of the target protein HLA-A2/Luc was demonstrated (See Supplementary  Figure 1 ).
For the identification of HLA-A2 expression in cells transfected with pcDNA3-HLA-A2/Luc plasmid, BHK-21 cells (4 Â 10 4 per well) were seeded into 24-well round-bottomed plate and after overnight incubation, BHK-21 cells were transfected with 1 mg of pcDNA3-HLA-A2, pcDNA3-HLA-A2/Luc or pcDNA3-No insert plasmid DNA using Lipofectamin 2000 reagent (Invitrogen, Carlsbad, CA, USA). After one day, the expression of HLA-A2 was measured by flow cytometry analysis after staining using PE-labeled mouse anti HLA-A2 antibody (BD Biosciences, San Jose, CA, USA). Analysis was carried out on a Becton-Dickinson FACScan with CELLQuest software (Becton Dickinson Immunocytometry System, Mountain View, CA, USA).
Cells
The human papillomavirus type 16 E7-expressing murine tumor model, TC-1, has been described previously. 27 In brief, human papillomavirus type 16 E6, E7 and the ras oncogene were used to transform primary Xenogenic MHC class-I DNA with CRT-E7 DNA vaccination TH Kang et al C57BL/6 mice lung epithelial cells to generate the TC-1 cell line. The DC-1 cells 28 were derived from a wellcharacterized dendritic cell line and were kindly provided by Dr Kenneth Rock (University of Massachusetts, Worcester, MA, USA). 29 These cell lines were cultured in vitro in RPMI 1640 supplemented with 10% fetal bovine serum, 50 U ml À1 of penicillin/streptomycin, 2 mM L-glutamine, 1 mM sodium pyruvate and 2 mM nonessential amino acids, and grown at 37 1C with 5% CO 2 .
In vivo electroporation and gene delivery
For the immunization of mice, control plasmid (pcDNA3-no insert), CRT-E7, HLA-A2, HLA-A3, HLA-A24 or OVA plasmid vectors were delivered intramuscularly followed by electroporation twice with a 1-week interval. Hair around the quadriceps femoris muscle of mice was removed. The muscle was then injected with 2 mg (1 mg of pcDNA3-CRT-E7 was mixed with 1 mg of pcDNA3-No insert, HLA-A2, HLA-A3, HLA-A24 or OVA) of plasmid DNA in 50 ml using the TriGrid Electroporation Delivery System (Ichor Medical Systems, San Diego, CA, USA). The electroporation protocol involved rectangular wave, direct-current pulses applied at 220 V cm À1 peak amplitude and 8% dusty cycle over 0.5 s. The TriGrid electroporation system consists of an electric pulse generator and a TriGrid array comprising four electrodes 2 mm in length with 2.5 mm interelectrode spacing.
Intracellular cytokine staining and flow cytometry analysis
Mice were immunized with 2 mg of the various DNA vaccines and received a booster with the same regimen 1 week later. Splenocytes were harvested 1 week after the last vaccination. Before intracellular cytokine staining, 6 Â 10 5 pooled splenocytes from each vaccination group were incubated for 16 h with either 1 mg ml À1 of E7 peptide (RAHYNIVTF) or OVA peptide (SIINFEKL) containing an MHC class-I epitope 26 for detecting E7 or OVA-specific CD8 + T cells. Cell-surface-marker staining of CD8 and intracellular cytokine staining for IFN-g using phycoerythrin-conjugate monoclonal rat antimouse CD8 antibody (BD Pharmingen, San Diego, CA, USA) and FITC-conjugated anti-mouse IFN-g antibodies (BD Pharmingen, San Diego, CA, USA) as well as flow cytometry analysis were carried out using conditions described previously. 30 Analyses were done on a Becton-Dickinson FACScan with CELLQuest software (Becton Dickinson Immunocytometry System, Mountain View, CA, USA).
Immunohistochemistry
For the immunohistochemistry, 1 mg of pcDNA-no insert or HLA-A2 plasmid DNA were injected in vivo by electroporation-mediated intramuscle injection into the mice. Muscle from the site of plasmid electroporation were fixed with 5% neutralized formalin and embedded in paraffin. The formalin-fixed and paraffin-embedded sections were deparaffinized and hydrated in xylene and serial alcohol solutions, respectively. And then sections were stained with hematoxylin and eosin for the visualization of cellular inflammation. For the antibody staining, the antigen retrieval was carried out in a pressure cooker with antigen-retrieval buffer pH 6 (DakoCytomation, Glostrup, Denmark) at 124 1C, for 30 s. Endogenous peroxidase was blocked by incubation in 3% H 2 O 2 for 10 min. LSAB À + (DakoCytomation; CD8 and CD11b/c) was used for immunohistochemical labeling. Non-specific binding of antibodies were blocked with serum-free protein block (DakoCytomation) for 15 min and then incubated with primary antibodies at 4 1C overnight. We used the following antibodies obtained from commercial suupliers: rat anti-F4/80 (CI:A3-1, 1:50, Abcam, Cambridge, MA, USA), rabbit anti-CD8 (EP1150Y, 1:500, Abcam) and rabbit anti-CD11b/c (1:200, Abcam) antibodies. The stain visualized using 3,3 0 -diaminobenzidine plus (DakoCytomation) and was lightly counterstained with hematoxylin, dehydrated in ethanol and cleared in xylene. The slides were covered and observed under a light microscope (Axioplot, Carl Zeiss, Jena, Germany). The counting of each antibody positive cells was performed as previously described. 19 The data were generated using 200 Â HPF (high power field) from three different fields for each muscle tissue.
Luciferase-based bioluminescence imaging
For the in vivo bioluminescence imaging, 1 mg of pcDNA3-HLA-A2/Luc or pcDNA3-Luc plasmid DNA were injected in vivo by electroporation-mediated intramuscle injection into the mice. The intensity of bioluminescence was checked on days 0 and 3 after injection. Image on day 0 was taken from 4 h later after injection. D-Luciferin was dissolved to 7.8 mg ml À1 in PBS, filter sterilized and stored at À80 1C. Mice were given D-luciferin by i.p. injection (200 ml per mouse, 75 mg kg À1 ) and anesthetized with isoflurane. In vivo bioluminescence imaging for Luc was conducted on a cryogenically cooled IVIS system (Xenogen, acquired by Caliper Life Sciences, Hopkinton, MA, USA) using Living Image acquisition and analysis software (Xenogen). Mice were then placed onto the warmed stage inside the light-tight camera box with continuous exposure to 1-2% isoflurane. Images were acquired 10 min after D-luciferin administration and imaged for 1 min. The levels of light from the bioluminescent cells were detected by IVIS camera system, integrated, and digitized. Region of interest from displayed images was designated around the injection sites and quantified as total photon counts using Living Image 2.50 software (Xenogen).
In vivo tumor treatment experiments
For the tumor treatment experiment, mice were challenged with 2 Â l0 5 TC-1 tumor cells per mouse in the tail vein to simulate hematogenous spread of tumors. 31 Four days after tumor challenge, mice were vaccinated and boosted 1 week later with pcDNA-No insert, HLA-A2, CRT-E7 or CRT-E7 and HLA-A2 by electroporation. Mice were monitored twice a week and sacrificed on day 35 after the last vaccination. The mean number of pulmonary nodules in each mouse was determined by experimenters blinded to the sample identity.
Long-term in vivo tumor protection experiments C57BL/6 mice (five per group) were vaccinated and received a booster with pcDNA-No insert, HLA-A2, CRT-E7 or CRT-E7 and HLA-A2 by electroporation. Seven weeks after the last vaccination, mice were Xenogenic MHC class-I DNA with CRT-E7 DNA vaccination TH Kang et al subcutaneously challenged with 1 Â l0 5 TC-1 cells per mouse in the right leg and evaluate long-term survival. Mice were monitored for the evidence of survival by palpation and inspection twice a week. The mice were killed at any time during the experiment if tumor size was over than 2 cm in the longest dimension.
Statistical analysis
All data are expressed as means ± s.d. and are representative of at least two separate experiments. Results for intracellular cytokine staining with flow cytometry analysis and tumor treatment experiments were evaluated by analysis of variance. Comparisons between individual data points were made using Student's t-test. In the tumor protection experiments, the principal outcome measure was time to tumor development. The event time distributions for different mice were compared using the Kaplan and Meier method and the log-rank statistic. Graphs were done using SigmaPlot program file (Systat Software). All P-values o0.05 were considered significant.
